Charles Cook

Charles Cook has over 18 years of experience in the life sciences industry. Charles began their career in 2003 as a Manager/Senior Manager of Chemical Manufacturing at Gilead Sciences, where they were responsible for tech transfer, validation and production of small molecule commercial and clinical APIs. In 2008, they moved to Genentech as a Senior Manager of Manufacturing Collaborations and CMC Team Lead. In 2010, they joined Reata Pharmaceuticals, Inc. as a Director of Process Chemistry, and in 2013, they became a Senior Director/Executive Director of Manufacturing at Raptor Pharmaceuticals. In 2014, they were appointed Vice President of Manufacturing and Tech Ops at Hyperion Therapeutics, Inc. (purchased by Horizon Pharma). In 2015, they became Vice President of CMC at Revolution Medicines and in 2016, they returned to Reata Pharmaceuticals, Inc. as Vice President of CMC. In 2018, they joined CMC SQUARED as a Principal Consultant and in 2021, they were appointed Vice President of CMC at NiKang Therapeutics Inc.

Charles Cook obtained a PhD in Organic Chemistry from The University of Texas at Arlington between 1990 and 1995.